SARS-CoV-2 3CLpro-IN-5 

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL^pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19)^[1].

IC50: 3.8 nM (3CL^pro)^[1].
EC50 for SARS-CoV-2 strains: 13.8 nM (α), 7.57 nM (δ), 9.01 nM (Om BA.1) and 17.1 nM (Om BA.2) ^[1].
EC50: 59.3 nM (SARS-CoV in 293TAT cells); 4.72 nM (MERS-CoV in 293TDPP4 cells); 1.67 nM (HCoV-OC43 in 293TAT cells)^[1].

SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL^pro with an IC₅₀ value of 3.8 nM^[1].
SARS-CoV-2 3CLpro-IN-5 has antiviral activity in 293TAT cells againsts various SARS-CoV-2 strains α, δ, Om BA.1 and Om BA.2 with EC₅₀ values of 13.8 nM, 7.57 nM, 9.01 nM and 17.1 nM, respectively^[1].
SARS-CoV-2 3CLpro-IN-5 has antiviral activity against various coronaviruses SARS-CoV (293TAT cells), MERS-CoV (293TDPP4 cells) and HCoV-OC43 (293TAT cells) with EC₅₀ values of 59.3 nM, 4.72 nM and 1.67 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SARS-CoV-2 3CLpro-IN-5 (oral, i.v.; 10, 100 mg/kg) has strong antiviral activity and favorable pharmacokinetic properties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

497.92

C₂₂H₂₆ClF₂N₅O₄

2913186-57-7

FC1=CC=CC2=C1C=C(C(N[C@H](C(NN(C([C@@](F)([H])Cl)=O)C[C@H]3C(NCC3)=O)=O)CC(C)C)=O)N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yuya Hirose, et al. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. J Med Chem  [Content Brief]